Abstract
Rapid detection of drug resistance in Mycobacterium tuberculosis is important for the successful treatment of tuberculosis. Fluoroquinolone and aminoglycoside resistance detection by molecular methods becomes more complex due to cross resistance among them. Thus, we aimed to determine cross-resistance and mutations in resistance genes for these drugs. A total of 336 multidrug-resistant tuberculosis (MDR-TB) cases received in Mycobacteriology laboratory were screened for phenotypic drug sensitivity testing for second-line drugs, i.e., ofloxacin, amikacin, kanamycin, and capreomycin. Molecular characterization of resistance was done by DNA sequencing of gyrA gene for fuoroquinolones (FQ), and multiplex allele-specific polymerase chain reaction (PCR) and PCR restriction fragment length polymorphism (RFLP) of rrs gene for aminoglycosides. Of 336 MDR-TB isolates, 12 were extensively drug-resistant tuberculosis and 219 were sensitive to all the drugs tested. Ofoxacin, amikacin, kanamycin, and capreomycin resistance was detected in 101 (30.1%), 23 (6.8%), 27 (8.1%), and 19 (5.6%) cases, respectively. Eight different mutations were detected in gyrA gene in ofloxacin-resistant isolates and A1401G nucleotide change in rrs gene were seen in 55.6% (15/27), 65.2% (15/23), and 68.4% (13/29) for kanamycin-, amikacin-, and capreomycin-resistant isolates, respectively. Information on second-line drug resistance-associated mutations could potentially be used for development of newer rapid diagnostic tests.
Article PDF
Avoid common mistakes on your manuscript.
References
World Health Organization. Global tuberculosis control report 2014. Geneva, Switzerland: World Health Organization; 2014. Available from: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf
Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011;38;516–28.
Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38;773–80.
Pitaksajjakul P, Wongwit W, Punprasit W, Eampokalap B, Peacock S, Ramasoota P. Mutations in the gyrA and gyrB genes of fluoroquinolone- resistant Mycobacterium tuberculosis from TB patients in Thailand. Southeast Asian J Trop Med Public Health 2005;36 Suppl 4;228–37.
Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009;53;4498–500.
Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004;48;596–601.
World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization; 2008. Available from: http://apps.who.int/iris/bitstream/10665/70500/1/WHO_HTM_TB_2008.392_eng.pdf
van Soolingen D, Hermans P W, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol 1991;29;2578–86.
Evans J, Segal H. Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. J Antimicrob Chemother 2010;65;897–900.
Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012;67;1088–93.
Lee AS, Tang LL, Lim IH, Wong SY. Characterization of pyr-azinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. Int J Infect Dis 2002;6;48–51.
Singh P, Jain A, Dixit P, Prakash S, Jaiswal I, Venkatesh V, et al. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. J Antibiot (Tokyo) 2015;68;63–6.
Singhal R, Reynolds PR, Marola JL, Epperson LE, Arora J, Sarin R, et al. Sequence analysis of fluoroquinolone resistance-associated genes gyrA and gyrB in clinical Mycobacterium tuberculosis isolates from patients suspected of having multidrug-resistant tuberculosis in New Delhi, India. J Clin Microbiol 2016;54;2298–305.
Ajbani K, Rodrigues C, Shenai S, Mehta A. Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India. J Clin Microbiol 2011;49;1588–90.
Perdigão J, Macedo R, Malaquias A, Ferreira A, Brum L, Portugal I. Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J Antimicrob Chemother 2010;65;224–7.
Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to ami-kacin, kanamycin and capreomycin: a systematic review. PLoS One 2012;7;e33275.
Fassihi A, Azadpour Z, Delbari N, Saghaie L, Memarian HR, Sabet R, et al. Synthesis and antitubercular activity of novel 4-substi-tuted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyri-dine-3,5-dicarboxamides. Eur J Med Chem 2009;44;3253–8.
Khoshneviszadeh M, Edraki N, Javidnia K, Alborzi A, Pourabbas B, Mardaneh J, et al. Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents. Bioorg Med Chem 2009;17;1579–86.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Yadav, R., Saini, A., Mankotia, J. et al. Genetic Characterization of Second-Line Drug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis from the Northern Region of India. J Epidemiol Glob Health 8, 220–224 (2018). https://doi.org/10.2991/j.jegh.2018.02.100
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/j.jegh.2018.02.100